The Council on Radionuclides and Radiopharmaceuticals (CORAR) is an association comprised of companies in the United States and Canada who manufacture and distribute radiopharmaceuticals, sealed sources, and radionuclides primarily used in medicine and life science research.  CORAR is tasked with advocating for regulations and legislation that facilitate the growth and viability of its member companies.  Specifically, CORAR focuses on manufacturing, transportation, safety, security, reimbursement, and regulatory issues that can impact the radiopharmaceutical and radionuclide industry.  CORAR must pursue a proactive agenda which includes education of the Congress and regulatory bodies on the benefits of radiopharmaceuticals and radionuclides to medical and life sciences.

Activities of CORAR include:

• To monitor and participate in the legislative and regulatory process at the federal, state, local and international levels to ensure the appropriate treatment of radiopharmaceuticals and radionuclides, and radioactive products used in life medical sciences.
• To maintain effective contact with regulatory and legislative staff to supply timely information to assist regulatory agencies and legislative bodies who are in the process of developing new or revised regulations, regulatory guidelines and legislation;
• To encourage a policy of appropriate and adequate reimbursement for costs of using radiopharmaceuticals under Medicare and other systems for health care coverage;
• To develop and encourage the use of industrial standards to assure safe, reliable and high quality products and services;
• To educate Congress, federal regulatory agencies, medical specialty societies, the public, and other medical trade groups on the benefits of radiopharmaceuticals;
• To develop and maintain an interactive association with medical, industrial, professional, and academic associations who share common concerns for the effective and safe utilization of radiopharmaceuticals and other radioactive products;
• To provide a forum for interests of the radionuclide and radiopharmaceutical industries.